New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
10:25 EDTPRGO, CPIXCumberland enters settlement with Paddock, Perrigo for Acetadote patent
Cumberland (CPIX) disclosed this morning that it entered into a settlement agreement with Paddock and Perrigo to resolve the challenges and the pending litigation between the company and each of Paddock and Perrigo (PRGO) involving its Acetadote patent. Under the agreement, Paddock and Perrigo admit that the Acetadote patent is valid and enforceable and that any Paddock or Perrigo generic Acetadote would infringe upon the Acetadote patent. In addition Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the Acetadote patent through its expiration currently scheduled for May 2026. The agreement provides, among other things, that within three days of execution, the parties will file with the respective Illinois and Delaware courts all necessary papers required to dismiss without prejudice all claims and counterclaims, motions and petitions asserted in the above referenced lawsuits In connection with the execution of the settlement agreement, Cumberland entered into a License and Supply Agreement with Paddock and Perrigo. Under the terms, if a third party receives final approval from the FDA to sell a generic Acetadote product, Cumberland will supply Perrigo with an authorized generic version of the Acetadote product. Perrigo agrees to sell the authorized generic and that it would share with Cumberland the net sales revenues.
News For CPIX;PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
17:36 EDTCPIXCumberland reports clinical, regulatory milestones
Subscribe for More Information
06:14 EDTPRGOPerrigo investor sentiment could improve this year, says Deutsche Bank
Deutsche Bank believes Perrigo investor sentiment remains poor and says it "wouldn't wait for things to look perfect" to buy the stock. Deutsche thinks a return to consistent financial results, earnings growth acceleration in Q2 following the close of the Omega acquisition, and a possible investor day around May 5 could drive improved sentiment on the name. It lowered its price target for Perrigo shares to $200 from $204 and keeps a Buy rating on the stock.
February 20, 2015
07:08 EDTPRGOAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 18, 2015
07:53 EDTPRGOPerrigo management to meet with UBS
Meetings to be held in Minneapolis/Milwaukee on February 18 hosted by UBS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use